# P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

> **NCT06973577** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 315 (actual)

## Conditions studied

- ADHD
- Anxiety
- Generalized Anxiety
- Social Anxiety Disorder

## Interventions

- **DRUG:** Centanafadine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06973577
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-26
- **Primary completion:** 2026-04-22
- **Final completion:** 2026-04-29
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06973577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06973577, "P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06973577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*